Galactose epimerase deficiency: lessons from the GalNet registry

Britt Derks1,2,3,4†, Didem Demirbas5, Rodrigo R. Arantes6, Samantha Banford7, Alberto B. Burlina3,8, Ana Cabrera9, Ana Chiesa10, M. Luz Couce3,11, Carlo Dionisi-Vici3,12, Matthias Gautschi13, Stephanie Grünewald14, Eva Morava15, Dorothea Möslinger16, Sabine Scholl-Bürgi3,17, Anastasia Skouma18, Karolina M. Stepien19, David J. Timson20^, Gerard T. Berry5† and M. Estela Rubio-Gozalbo1,2,3,4*†

Abstract

Background: Galactose epimerase (GALE) deficiency is a rare hereditary disorder of galactose metabolism with only a few cases described in the literature. This study aims to present the data of patients with GALE deficiency from different countries included through the Galactosemia Network to further expand the existing knowledge and review the current diagnostic strategy, treatment and follow-up of this not well characterized entity.

Methods: Observational study collecting medical data from December 2014 to April 2022 of 22 not previously reported patients from 14 centers in 9 countries. Patients were classified as generalized or non-generalized based on their genotype, enzyme activities in different tissues and/or clinical picture and professional judgment of the treating physician.

Results: In total 6 patients were classified as generalized and 16 as non-generalized. In the generalized group, acute neonatal illness was reported in 3, cognitive and developmental delays were present in 5 and hearing problems were reported in 3. Four generalized patients were homozygous for the genetic variant NM_001008216.2:c.280G > A (p.Val94Met). In the non-generalized group, no clearly related symptoms were found. Ten novel genetic variants were reported in this study population.

Conclusion: The phenotypic spectrum of GALE deficiency ranges from asymptomatic to severe. The generalized patients have a phenotype that is in line with the 9 described cases in the literature and prescribing dietary interventions is the cornerstone for treatment. In the non-generalized group, treatment advice is more difficult. To be able to offer proper counseling, in addition to red blood cell enzyme activity, genetic studies, transferrin glycoform analysis and enzymatic measurements in fibroblasts are recommended. Due to lack of facilities, additional enzymatic testing is not common practice in many centers nor a tailored long-term follow-up is performed.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction

Galactosemia type III (OMIM #230,350), also known as galactose epimerase deficiency or UDP-galactose-4-epimerase deficiency (GALE; EC 5.1.3.2), is one of the hereditary galactosemias [1], a group of inherited disorders of galactose metabolism. The GALE enzyme is the third enzyme in the Leloir pathway, the predominant route of galactose metabolism. Human GALE functions as a homodimer [2] and catalyzes the conversion of uridine diphosphate galactose (UDP-gal) to uridine diphosphate glucose (UDP-glc) [3, 4] maintaining an equilibrium ratio of UDP-Gal to UDP-Glc of one to three [5]. GALE also catalyzes the interconversion of uridine diphosphate-N-acetyl-galactosamine (UDP-GalNAc) and uridine diphosphate-N-acetyl-glucosamine (UDP-GlcNAc) [6], all necessary for the glycosylation of proteins and lipids [7].

The clinical presentation of GALE deficiency is considered a continuum ranging from a benign peripheral form to an intermediate form to a severe generalized form, depending on the affected tissues and the degree of GALE impairment [8–10]. The benign peripheral form of GALE deficiency has an estimated prevalence of 1:6,700–1:60,000 and the generalized form is considered ultra-rare [10]. The peripheral form was first reported by Gitzelmann [11, 12], describing patients in whom GALE impairment was restricted to circulating white blood cells with less than 50% of normal enzyme levels [1, 10]. The intermediate form has been defined as a deficient GALE enzyme activity in red and white blood cells in combination with normal or near-normal levels of GALE in fibroblasts, liver, phytohemagglutinin (PHA) stimulated leukocytes and Epstein Barr virus (EBV) transformed lymphoblasts. In general, patients with the peripheral form are asymptomatic and undergo a normal growth and development despite raised galactose-1-phosphate (Gal-1-P) in the erythrocytes [1, 10]. The intermediate form has been defined as a deficient GALE enzyme activity in red and white blood cells with less than 50% of normal enzyme levels (not profoundly decreased) in other non-peripheral cells [9, 10]. Patients with the intermediate form show a variable clinical phenotype ranging from asymptomatic to neonatal transient illness, resolved upon dietary galactose restriction. However, their long-term outcome is still unclear [9]. The generalized form of GALE deficiency appears to be an extremely rare disorder, with only nine patients (five females and four males) of four families reported in the literature so far [13, 14]. In patients with generalized GALE deficiency, the enzyme activity is profoundly decreased in all tissues tested [9]. The first case of generalized GALE deficiency was reported in 1981, describing a newborn that presented on day five with a severe clinical picture similar to classic galactosemia and with a lack of GALE activity in red blood cells and fibroblasts [15]. Dysmorphic features as well as other long-term complications apparent from birth have been reported in other patients with generalized GALE deficiency [13, 14]. These patients are from highly consanguineous families, making it questionable which symptoms are attributable to the GALE deficiency.

Various genetic variants have been identified and described in the GALE gene located on chromosome 1p36.11 [16]. The most severe defects in GALE protein were observed in NM_001008216.2:c.280G > A (p.Val94Met), NM_001008216.2:c.269G > A (p.Gly90Glu) and NM_001008216.2:c.548 T > C (p.Leu183Pro) genetic variants. Homozygosity of NM_001008216.2:c.280G > A (p.Val94Met) has been found in the majority of patients with the generalized phenotype [17, 18].

In 2012, the international network of galactosemias (GalNet, https://www.galactosemianetwork.org) created a web-based patient registry including galactosemia type I, II and III [19]. This study aims to present the data of patients with GALE deficiency from different countries included through the GalNet network to further expand the existing knowledge and review the current practice diagnostic strategy, treatment and follow-up of this not well characterized entity.

Results

Patients’ characteristics

In this study, 22 patients, who were previously unreported in the literature with a median age of 9.5 years (range 7 months—37 years) were included. The majority, 77.3% (17/22) of patients were detected by newborn screening (NBS). There were 40.9% females and 59.1% males. The patients originated from 9 countries and 14 different centers (Table 1). Four patients came from a consanguineous family. Seventy-three percent of the patients were Caucasian (see Additional file 1). In 3 patients, additional genetic testing (Whole Exome Sequencing (WES)) was performed and revealed no other genetic variants. In total, 6 patients were categorized as generalized and 16 as non-generalized. The non-generalized group likely comprises patients with peripheral and intermediate forms. Due to the young population age, the development of long-term complication in asymptomatic patients could not be ruled out.

Keywords: Galactose epimerase deficiency, Galactosemia type III, Galactosemias Network, Galactose-restricted diet
Diet
All generalized patients followed a galactose-restricted diet initiated within the first month of life. Four of them followed a strict diet (lactose free and restrictions of non-dairy galactose). In the non-generalized group, 8 patients followed a galactose-restricted diet with onset within the first month of life in 7. Two non-generalized patients started a diet in the neonatal period, but diet was withdrawn during infancy. Six non-generalized patients did not follow a diet.

Phenotypic spectrum
Neonatal illness
Acute neonatal illness was defined as having one of the following symptoms: icterus, encephalopathy (decreased consciousness with or without neurological symptoms), bleeding diathesis (abnormal prothrombin time (PT) and/or activated partial thromboplastin time (APTT)), infection signs or hypoglycemia (glucose < 2.6 mmol/L).

In the generalized group, 3 showed acute neonatal illness (see Additional file 1). These patients were not detected by NBS. In the peripheral group, acute neonatal illness was reported in 7 of the 16 patients, mainly due to the presence of icterus and/or hypoglycemia (see Additional file 1).

Long-term follow-up
Regarding the brain follow-up, developmental delay was reported in 5 of the 6 patients categorized as generalized, 4 suffered from both motor and mental delays and 1 suffered from motor delays. Language delay was reported in 4, speech disorders in 2 and learning disabilities in 2. Due to the lack of NBS in the corresponding countries, none of them were diagnosed following NBS. In these patients, GALE deficiency was suspected based on their clinical picture and after exclusion of classic galactosemia. Other reported neurological symptoms mentioned in the generalized group included general motor abnormalities in 2 and gait problems in 2 (see Additional file 1). In the non-generalized group, 1 patient suffered from gait problems (see Additional file 1).

Female gonadal follow-up was reported in 2 patients at the age of 24 and 34 years with generalized GALE deficiency. Neither of these patients showed delayed puberty or signs of primary ovarian insufficiency (POI) (see Additional file 1). Their menstrual cycles were regular and normal. Gonadal ultrasound revealed no abnormalities (see Additional file 1). Both patients have not yet tried to conceive. In the non-generalized group, information on the female gonadal follow-up was not available mainly due to the young population age.

Regarding the bone health, 2 of the 3 reported patients with generalized GALE deficiency showed decreased levels of vitamin D. In these 3 patients, a dual-energy x-ray absorptiometry (DEXA) was performed, which showed the presence of osteopenia (T-scores − 1.8) and of a lower bone density compared to peers (Z-scores: − 0.23, − 0.9, − 1.8). The physical activity was rated below World Health Organization (WHO) standards in these 3 patients (see Additional file 1). No bone fractures were reported. In total, 4 generalized patients used calcium and vitamin D supplements.

In the non-generalized group, vitamin D levels were measured in 5 patients, 3 of them showed vitamin

### Table 1  Participating countries and center

| Country     | Center                                                                 | NBS | Number of patients |
|-------------|------------------------------------------------------------------------|-----|--------------------|
| Argentina   | Hospital de Niños Ricardo Gutièrrez, Rosario                          | Yes | 2                  |
| Austria     | Universitätsklinik für Pädiatrie, Tirol Kliniken GmbH, Innsbruck      | Yes | 1                  |
|             | Medizinische Universität Wien Vienna                                   | Yes | 1                  |
| Brazil      | Hospital das Clinicas da Universidade Federal de Minas Gerais         | No  | 1                  |
| Greece      | Institute of Child Health, Athens                                      | Yes | 3                  |
| Italy       | Bambino Gesu Children’s Research Hospital, Roma                       | Yes | 1                  |
|             | Division of Inherited Metabolic Diseases, University Hospital, Padova  | Yes | 2                  |
| Spain       | University Clinical Hospital of Santiago de Compostela                 | Yes | 2                  |
| Switzerland | Insel spital, University Hospital, Bern                                | Yes | 2                  |
|             | University Children’s Hospital, Zürich                                 | Yes | 1                  |
| United Kingdom | Salford Royal NHS Foundation Trust Salford                           | No  | 3                  |
|             | Great Ormond Street Hospital, London                                  | No  | 1                  |
| USA         | Boston Children’s Hospital                                            | Yes | 1                  |
|             | Mayo Clinic, Rochester, Minnesota                                     | Yes | 1                  |
| Total       |                                                                       |     | 22                 |
D deficiency and all 3 did not follow a diet. No data of DEXA-scans was available. No bone fractures were reported. The physical activity was assessed in 7 patients, all within the normal levels according to the WHO standards. Eleven patients used vitamin D supplements, 1 used calcium supplements and 1 used both (see Additional file 1).

In addition, the presence of hearing impairments, hematological abnormalities and short stature were assessed. Hearing impairments were present in 3 generalized patients and 1 non-generalized patient. Hematological abnormalities were not reported in the generalized group. In the non-generalized group, one patient was reported with thrombocytopenia worsening with intercurrent infections. Short stature was present in 4 generalized patients and 1 non-generalized patient (see Additional file 1). In one generalized patient, low levels of IgM and IgA were found, regarded as of no clinical relevance.

Metabolites
Data on metabolites is presented in Table 2. In the generalized group, data on neonatal Gal-1-P was present in 2 patients and was elevated in both. In 1 patient, the urinary galactitol was recently measured and was within the normal range. In 4 patients, glycosylation patterns of transferrin were analyzed to investigate the presence of glycosylation defects. One patient avoided dairy products from the start of birth and has never been on a strict diet. In the neonatal period, his transferrin revealed an abnormal pattern (type 1 congenital disorder of glycosylation (CDG)-pattern), which normalized after the neonatal period without dietary changes. Two other generalized patients showed abnormal type 1 CDG patterns before initiation of diet, which normalized after the diet was initiated. Surprisingly, one generalized patient showed normal transferrin patterns after the galactose-restricted diet was initiated a few hours in advance of the test sampling. In the non-generalized group, data on total galactose in blood was available in 11 patients, 7 showed elevated levels in the neonatal period/before diet. Neonatal Gal-1-P was measured in 11 patients and elevated in 8. In 6 patients the urinary galactitol was measured and was (near)-normal. Information on the transferrin patterns was available in 4 patients, which showed normal patterns before the initiation of a galactose restriction diet or without a diet.

Enzyme measurement and genotypic spectrum
The GALE gene variants (NM_001008216.2) were reported in 6 generalized patients and in 15 non-generalized patients. In the generalized group, 4 patients were homozygous for the variant NM_001008216.2:c.280G > A (p.Val94Met). Their enzyme activities measured in erythrocytes ranged from undetectable to 4.7%. In 2 patients, additional enzyme activities measured in fibroblasts were performed and were undetectable. One generalized patient was compound heterozygous for the variant NM_001008216.2:c.280G > A (p.Val94Met) and NM_001008216.2:c.284G > A (p.Gly95Asp) and showed an enzyme activity of 8.3% measured in the erythrocytes. The other generalized GALE deficient patient was compound heterozygous for NM_001008216.2:c.632A > G (p.Tyr211Cys) and NM_001008216.2:c.820G > C (p.Gly274Arg). In this patient, the GALE enzymatic level was undetectable in erythrocytes and fibroblasts (Fig. 1).

In total, 10 unpublished genetic variants were reported in this study population, namely NM_001008216.2:c.280G > A (p.Val94Met), NM_001008216.2:c.284G > A (p.Gly95Asp), NM_001008216.2:c.318_319del (p.Arg106SerfsTer2), NM_001008216.2:c.318_319del (p.Arg106SerfsTer2), NM_001008216.2:c.466C > G (p.Pro156Ala), NM_001008216.2:c.632A > G (p.Tyr211Cys), NM_001008216.2:c.646G > A (p.Ala216Thr), NM_001008216.2:c.647C > T (p.Ala216Val), NM_001008216.2:c.651C > T (p.Ala217Val), NM_001008216.2:c.728A > C (p.His243Pro), NM_001008216.2:c.796A > C (p.Ile266Leu), NM_001008216.2:c.820G > C (p.Gly274Arg), NM_001127621.2:c.214G > A (p.Ala72Thr) and NM_001127621.2:c.214G > A (p.Ala72Thr) and NM_001008216.2:c.237G > A (p.Lys79 = ). The latter is a silent genetic variant affecting exon 4 and could therefore not be depicted in Fig. 2. A second variant in the GALE gene has not yet been identified in the patient with the silent genetic variant, but there may be another variant in the intronic regions. None of these unpublished variants were described on the Genome Aggregation Database (gnomAD; https://gnomad.broadinstitute.org/). In Fig. 2, these variants are depicted in the crystal structure of GALE in complex with UDP-glucose and NADH.

Discussion
In this study, we describe the phenotypic and genotypic spectrum of 22 GALE deficient patients, 6 were classified as generalized and 16 as non-generalized.

Phenotypic spectrum
So far, 9 individuals from 5 families are described in the literature with generalized GALE deficiency [13–15, 17, 20–22]. Patients with generalized GALE deficiency do develop acute clinical symptoms similar to classic galactosemia when they are exposed to galactose [9], which resolve when the patient is initiated on a galactose-restricted diet. However, despite the galactose-restricted diet, some patients with generalized GALE deficiency are reported with long-term complications. The majority of these reported patients showed hepatic abnormalities (8/9), short stature (7/7), developmental delay (6/6), hypotonia (6/8), sensorineural hearing loss (4/7),
### Table 2: Metabolites in generalized and non-generalized patients

| Patient | Genotype and enzyme activity | Total galactose in blood | Neonatal Gal-1-P | Urinary galactitol | Transferrin | Pattern: normal/abnormal |
|---------|------------------------------|--------------------------|------------------|-------------------|-------------|-------------------------|
|         |                              | < 20 mg/dL               | < 10 mg/dL or < 0.05 µmol/g Hb | 2–81 mmol/mol creatinine |              |                         |
| **Generalized** |                             |                          |                  |                   |             |                         |
| P1      | c.[280G > A];[284G > A]     | NR                       | NR               | Recent – 11.0     | Neonatal period – Abnormal type I pattern | Most recent – normal |
|         | RBC: 8.3%                   |                          |                  |                   |             |                         |
| P2      | c.[280G > A];[280G > A]     | NR                       | 26 mg/dL         | NR                | Before initiation of diet – abnormal type I pattern | After initiation of diet – normal |
|         | RBC: 4.7%                   |                          |                  |                   |             |                         |
| P4      | c.[280G > A];[280G > A]     | NR                       | 44 mg/dL         | NR                | Before initiation of diet – abnormal type I pattern | After initiation of diet – normal |
|         | RBC and fibroblast: undetectable |                          |                  |                   |             |                         |
| P6      | c.[632A > G];[820G > C]     | NR                       | NR               | NR                | Few hours after diet initiation – normal | After initiation of diet – normal |
|         | RBC and fibroblast: undetectable |                          |                  |                   |             |                         |
| **Non-generalized** |                             |                          |                  |                   |             |                         |
| P7      | c.[647C > T];[728A > C]     | Neonatal – 43.0          | 3.4 mg/dL        | Neonatal – 19.1   | NR          |                         |
|         | RBC: 17.5%; lymphoblast: 40.1% |                          |                  | recent – 83.0     |             |                         |
| P8      | c.[755 T > C];[755 T > C]   | Neonatal – 14            | 2.9 µmol/g Hb    | NR                | NR          |                         |
|         | RBC: 4.1%                   |                          |                  |                   |             |                         |
| P9      | c.[284G > A];[284G > A]     | Neonatal – 12.8          | 2.1 µmol/g Hb    | NR                | NR          |                         |
|         | RBC: 3.2%                   |                          |                  |                   |             |                         |
| P10     | c.[449C > T];[449C > T]     | Neonatal – 62.9          | 10.8 mg/dL       | NR                | NR          |                         |
|         | RBC: 0.0%                   | recent – 6.4             |                  |                   |             |                         |
| P11     | c.[646G > A];[646G > A]     | Neonatal – > 50          | NR               | NR                | NR          |                         |
|         | RBC: 17.5%; lymphoblast: 40.1% |                          |                  |                   |             |                         |
| P12     | c.[796A > C];[538G > A]     | Neonatal – 36.4          | NR               | NR                | NR          |                         |
|         | RBC: 4.1%                   | Recent – 1.6             |                  |                   |             |                         |
| P13     | c.[755 T > C];[290C > T]    | Neonatal – 35.4          | NR               | NR                | NR          |                         |
|         | RBC: 4.1%                   | Recent – 2.1             |                  |                   |             |                         |
| P14     | c.[484 T > A];[820G > C]    | Before diet – 31         | 33.1 mg/dL       | NR                | NR          |                         |
|         | RBC: 33.3%                  |                          |                  |                   |             |                         |
| P15     | c.[755 T > C];[755 T > C]   | Before diet – 19         | 27.9 mg/dL       | NR                | NR          |                         |
|         | RBC: 23.1%                  |                          |                  |                   |             |                         |
| P16     | c.[318_319del];[658C > T]   | Neonatal – 80            | 9.5 mg/dL        | NR                | NR          |                         |
|         | RBC: 4.1%                   | Recent – 3.5             |                  |                   |             |                         |
| P17     | c.[647C > T];[602C > T]     | NR                       | 51 mg/dL         | Varies between 2 and 19 | No diet – normal |
|         | RBC: 6.4%                   |                          |                  |                   |             |                         |
| P18     | c.[647C > T];[602C > T]     | NR                       | 69.7 mg/dL       | Varies between 4 and 60 | No diet – normal |
|         | RBC: 4.5%                   |                          |                  |                   |             |                         |
| P20     | RBC 30.0%                   | NR                       | 5.0 mg/dL        | Recent – 1.17     | NR          |                         |
| P21     | c.[602C > T];[214G > A]     | NR                       | NR               | Recent – 1        | No diet – normal |
|         | RBC: 0.0%                   |                          |                  |                   |             |                         |
| P22     | Heterozygous                | Recent – 2.3 mg/dL       | 36.9 mg/dL       | Neonatal – 100    | Before initiation of diet – normal |
|         | c.[237G > AR];[820G > C]    |                          |                  |                   |             |                         |
|         | RBC: 31.4%                  |                          |                  |                   |             |                         |

*P = patient; NR = not reported*
micrognathia (4/6), flexion deformities of the fingers (3/6), hip dysplasia (3/7), cataracts (3/8) and renal dysfunction (1/6) [9]. In our study population, we included 6 patients with generalized GALE deficiency from 4 different families. In Additional file 2, the clinical picture of these 6 patients compared to the 9 previously published
patients with generalized GALE deficiency is summarized. The phenotype of our patients is comparable to the phenotype described in the literature. In our study population, the gonadal follow-up was reported in two female patients, sisters (age of follow-up 24 and 34 years) with generalized GALE deficiency. Interestingly, these patients did not show any signs of POI. This is in contrast to classic galactosemia, where 80% of the female patients suffer from POI [23], but is in line with previous findings of female patients with generalized GALE deficiency. Walter et al. (1999) [13] reported a female patient with generalized GALE deficiency that was severely affected, but did not show any signs of ovarian dysfunction. However, due to the small study population, these results should be interpreted with caution. Further research is needed to investigate whether or not there is a link between POI and GALE deficiency. Another resemblance between our study population and the described patients in the literature, is the high consanguinity rate, raising the question to what extent GALE variants or homozygosity for other autosomal recessive alleles were responsible for their phenotype and dysmorphic features. However, in our study population, a WES was performed in 3 generalized patients which revealed no other genetic variants than GALE variants.

Infants with intermediate GALE deficiency are usually asymptomatic in the neonatal period, even when they do not follow a galactose-restricted diet. However, in these patients the long-term outcomes and the effects of dietary interventions remain unclear [9]. A prospective follow-up could be helpful to answer the question whether dietary intervention is necessary. Alano et al. (1998) [24] described a GALE deficient patient following no specific diet that remained clinically well in the newborn period. At the age of 2 years, this patient developed intellectual and motor delays. The cause of the developmental delay was unknown, and it was stated that the influence of GALE deficiency could not be ruled out. However, in the general population, 15% of 3–17 years old children have at least one developmental delay [25].

Usually, newborns with peripheral GALE deficiency ingesting dairy milk are asymptomatic and are only detected if elevated levels of galactose are measured with NBS [9, 11]. Even without a diet, these patients appear to remain asymptomatic [9]. In our study population, 6 non-generalized patients were reported with acute neonatal illness, mostly based on the presence of icterus and/or hypoglycemia. However, hypoglycemia and jaundice are also frequent in newborns in the general population [26, 27]. In our study population, the majority of non-generalized patients were asymptomatic and no clearly related symptoms to the GALE deficiency were found. However, due to the young age of the study population, it is difficult to exclude the development of symptoms on the long-term.

Genotype

Due to the rarity of GALE deficiency, little is known about specific genotype–phenotype correlations. However, a few GALE genetic variants are clearly associated with a mild or severe phenotype. Homozygosity for the variant NM_001008216.2:c.280G>A (p.Val94Met) is associated with a severe phenotype [14]. This is in line with our findings, as 4 of the 6 patients with generalized GALE deficiency were homozygous for this variant. Timson et al. (2013) [28] found that this variant does not lead to changes in the dynamics and stability of the enzyme but does lead to changes in the active site dynamics. Because of this change, the binding of the substrate and probably the cofactor could be less stable. Other genetic variants have also been described in the literature that are associated with the peripheral or intermediate form [10, 29]. In our study population, 9 previously unpublished variants were reported. It is difficult to predict the in vivo effect of genetic variants on the protein structure and function without molecular dynamic simulations or in vitro studies (see Fig. 2 for locations of residues affected by point mutations). Despite this, it is likely that changes in the residues that form part of the active site will have a more predictable effect on the protein function. The genetic variants NM_001008216.2:c.280G>A (p.Val94Met), NM_001008216.2:c.632A>G (p.Tyr211Cys) and NM_001008216.2:c.284G>A (p.Gly95Asp) all form part of the substrate binding site and are therefore likely to impact substrate binding. The substitution of a negatively charged Asp residue for the neutral Gly-95 will likely have a substantial impact. The NM_001008216.2:c.820G>C (p.Gly274Arg) and NM_001008216.2:c.493G>A (Glu165Lys) substitutions also involve a change in charge. Timson et al. (2013) [30] predicted that NM_001008216.2:c.493G>A (Glu165Lys) causes a severe variant due to its interaction with the Lys-161 in the active site. Change in the polarity of the parts of the protein chain (NM_001008216.2:c.755T>C (p.Ile252Thr) and NM_001008216.2:c.290C>T (Ser97Leu)) could adversely affect protein folding. Changes in the residues of the dimer interface, as in NM_001008216.2:c.484T>A (p.Phe162Ile) could cause disruption in the proteins’ ability to dimerize. Substitution of proline residues, as in NM_001008216.2:c.466C>G (p.Pro156Ala) and NM_001008216.2:c.728A>C (p.His243Pro) can be particularly harmful as proline normally ends an α-helix. The substitution of smaller residues for larger ones (NM_001008216.2:c.658C>T (p.Arg220Trp); NM_001008216.2:c.449C>T (p.Thr150Met)) can impact the flexibility of the protein. Proteins require optimal flexibility for full
activity. NM_001008216.2:c.449C>T (p.Thr150Met) is thought to have an intermediate effect through its interaction with Ser-132 [30]. It is difficult to predict the structure changes in NM_001008216.2:c.646G>A (p.Ala216Thr), NM_001008216.2:c.647C>T (p.Ala216Val), NM_001008216.2:c.796A>C (p.Ile266Leu) and NM_001008216.2:c.538G>A (p.Ala180Thr) due to the relatively conservative nature of the variation.

Although the NM_001008216.2 (GALE):c.237G>A variation generates a synonymous coding effect at the protein level (p.(Lys79=)); the variant itself is predicted to alter a splice donor site. It causes a decrease in splicing signal predicted by different algorithms (MaxEnt: −51.5%, NNSPLICE: −64.1%, SSF: −14.2% and HSF: −11.2%). The allele frequency for this variant is 0.018475% in the African/African American population and it is not observed in other populations (gnomAD v2.1.1).

Summarizing, the novel genetic variant NM_001008216.2:c.632A>G (p.Tyr211Cys) is probably associated with generalized GALE deficiency and the novel genetic variants NM_001008216.2:c.290C>T (Ser97Leu), NM_001008216.2:c.658C>T (p.Ile220Thr) and severe thrombocytopenia. In addition to NM_001008216.2:c.151C>T (p.Arg51Trp), the variant NM_001008216.2:c.484T>A (p.Phe162Ile) and NM_001008216.2:c.728A>C (p.His243Pro) are probably associated with the non-generalized (intermediate or peripheral) form of GALE deficiency.

Diagnostic burden

When a GALE deficiency is suspected, the diagnosis can be established by diminished GALE enzyme activity in red blood cells (RBC) and/or by the identification of GALE pathogenic variants [9]. However, in an effort to classify the patient, additional GALE enzyme activities should be measured in fibroblasts or lymphoblasts. Enzymatic stability and catalytic efficiency of the GALE enzyme could be causative factors in the continuum of GALE deficiency [31], since patients with peripheral GALE deficiency show normal enzyme activity in liver and fibroblasts versus patients with generalized GALE deficiency who show profoundly decreased enzyme activity in other cell types, such as liver and fibroblasts [9, 32].

It is not usual practice in many centers to perform additional investigations in other tissues and or genetic testing to better classify the deficiency and consequently tailor the follow-up. GALE activity measurement such as in fibroblasts, genetic testing - preferably a WES when consanguinity is present – and metabolite testing is only available in a few centers.

Additional studies are desired in order to decide whether or not to initiate a galactose-restricted diet. In our study population, 8 patients classified as non-generalized – based on their clinical picture – do follow a galactose-restricted diet.

Glycosylation studies

Glycosylation studies such as serum transferrin glycoform analysis, may be a valuable tool in determining whether dietary restrictions are necessary. In addition to its function in the Leloir pathway, GALE also catalyzes the interconversion of UDP-N-acetyl-galactosamine (UDP-GalNAc) and UDP-N-acetyl-glucosamine (UDP-GlcNac). Abnormal production of UDP-Glc, UDP-Gal, UDP-GalNAc and UDP-GlcNac can alter glycans [33, 34]. In generalized GALE patients, abnormal serum transferrin glycosylation patterns normalizing after the initiation of diet have been observed [13, 14]. The abnormal patterns found in GALE deficient patients are consistent with the serum transferrin glycosylation patterns in classic galactosemia. Sturiale, et al. (2005) [35] demonstrated partial deficiency of whole glycans of serum transferrin in classic galactosemia patients characterized by increased fucosylation and branching similar to congenital defects of glycosylation type I. These abnormalities of transferrin N-glycan biosynthesis restore after the initiation of diet [35].

Glycosylation is also important for the biogenesis of platelets and the homing of hematopoietic cells, glycosylation defects may be the cause for hematological abnormalities seen in a few GALE deficient patients. N-acetyllactosamine, a dimer of galactose and UDP-galNAc, is abundantly present on β1-integrin, an important membrane protein on platelets for homing and extracellular interactions. Thus, GALE deficiency may lead to abnormal glycosylation of β1-integrin causing either insufficient homing of megakaryocytes and platelet progenitor cells and impaired interaction with extracellular matrix. Seo et al. (2019) [36] reported 6 consanguineous related individuals with homozygosity for NM_001008216.2:c.151C>T (p.Arg51Trp) and severe thrombocytopenia. In addition to NM_001008216.2:c.151C>T (p.Arg51Trp), the variant NM_001008216.2:c.449C>T (p.Thr150Met) has also been associated with hematologic and immune abnormalities [37]. In our study, one patient with homozygosity for NM_001008216.2:c.449C>T (p.Thr150Met) was included and was reported with thrombocytopenia, which worsened during intercurrent infections. Thus, GALE should be suspected in patients suffering with thrombocytopenia, dysmegakaryopoiesis and hemolytic anemia [37].

Newborn screening

In some countries, NBS includes GALE deficiency as part of screening for galactosemia, either as a secondary target disorder, or as an additional finding (see Table 1). This is possible if total galactose is measured as first tier
parameter. GALE deficiency is suspected when newborn screening shows increased total galactose (specifically Gal-1-P), but normal GALT activity. Efforts to reduce the number of false positives of the screening for classic galactosemia tend to use GALT activity as exclusive first tier, which precludes screening for GALE deficiency [38]. From 1968 to 2019, 30 cases with GALE deficiency were found with increased total galactose and normal GALT activity in Switzerland. This equates to an estimated incidence of 1:133,604 (personal communication, Prof Matthias Baumgartner, medical head of the Swiss NBS program). Since the emergence of NBS for GALE deficiency in several countries, more patients are diagnosed with GALE deficiency. For an efficient and safe NBS, it will be important to be able to clearly distinguish between cases of purely peripheral GALE deficiency, which can be considered as a biochemical variant that does not need treatment and is thus in regard to NBS a false positive, and the generalized form that needs a galactose-restricted diet in order to prevent disease symptoms. However, for the intermediate form of GALE deficiency this is not yet clear.

**Metabolites**

Patients with GALE deficiency are unable to synthesize UDP-gal by the pyrophosphorylase pathway and are therefore dependent on exogenous dietary galactose [14, 15]. On the other hand, dietary restriction of galactose is desired to prevent the development of acute symptoms. In the neonatal period, infants with GALE deficiency ingesting dairy milk show elevated Gal-1-P levels in the erythrocytes and elevated urinary galactose and galactitol concentrations. Toxic levels of Gal-1-P and galactitol may be responsible for the development of acute neonatal symptoms in patients with generalized and intermediate GALE deficiency [39]. These Gal-1-P levels range from >30 mg/dL in patients with intermediate or peripheral deficiency to 170 mg/dL in patients with generalized deficiency [9].

**Recommendations and follow-up**

Standardized diagnosis, treatment and follow-up are recommended to truly clarify the phenotypic spectrum. When patients show multiple symptoms and GALE

---

**Fig. 3** Schematic recommendation for standardized diagnosis, treatment and follow-up in GALE deficiency. These recommendations are based on the collected information from our study population and the international clinical guideline of classic galactosemia (CG). a: GALE enzymatic and genetic testing is needed for classification (generalized, intermediate or peripheral). In the presence of genetic variants clearly associated with a peripheral/intermediate/generalized form, further enzymatic testing in non-peripheral cells is not needed. If the given genotype is uncertain, the whole work up of GALE enzymatic and genetic testing is advised. b: It is recommended to perform a WES in consanguineous families or when other genetic conditions could be responsible for the genotype. c: Evidence is lacking whether or not to start a galactose-restricted diet in patients with intermediate GALE deficiency. The long-term outcomes and effect of dietary intervention remain unclear. d: Periodic brain follow-up is recommended. If learning disabilities, speech/language and/or motor and/or psychosocial problems are noted, adequate testing for in-depth assessment is advised. e: Gonadal follow-up is recommended due to the gap of knowledge in this entity regarding possible gonadal dysfunction. It is recommended to evaluate the presence of ovarian dysfunction in females and the presence of cryptorchidism in males. f: Bone health follow-up is advised to monitor periodically. Following the guidelines for CG, a DEXA-scan is recommended from the age of 8–10 years. g: Hearing screening is recommended in the first year of life. Short stature has been regularly reported, so it is recommended to evaluate the length periodically. Welling L, et al. Galactosemia Network (GalNet). International clinical guideline for the management of classical galactosemia: diagnosis, treatment, and follow-up. J Inherit Metab Dis. 2017;40(2):171–176. https://doi.org/10.1007/s10545-016-9990-5. Epub 2016 Nov 17. PMID: 27,858,262; PMCID: PMC5306419
deficiency is suspected, exclusion of other genetic conditions related to these symptoms is helpful. Based on the current insights and gaps in knowledge of this rare entity, a schematic overview with recommendations for diagnosis, treatment and follow-up is created (Fig. 3).

Study limitations
This study was limited by the small study population due to the low prevalence of the disease, the retrospective nature of data collection, and no standardized methods of follow-up.

Conclusion
We described the phenotypic spectrum of 22 patients with GALE deficiency, 6 of whom were classified as generalized. In total 10 previously unpublished GALE variants were identified. Not only genetic variants and affected enzymatic tissues, but also the clinical picture, should be taken into account to classify the patient.

In many centers, additional enzymatic or genetic testing to better classify the deficiency and thus the follow-up is not part of common practice due to lack of facilities to measure GALE enzyme activities in other cells rather than RBC. It is important to distinguish among GALE patients who need dietary intervention (generalized and intermediate) versus those who probably do not (peripheral). In addition to the clinical picture, investigating abnormal glycosylation, such as serum transferrin, may be of help in the decision to start dietary galactose restriction or not. The systematic follow-up of the clinical and biochemical follow-up including long-term outcome of this group of patients should be standardized worldwide to gain a better understanding of this entity.

Patients and methods

Ethics statement
Rubio-Gozalbo et al. (2019) [23] described the establishment of the GalNet in 2012 and the implementation of an online patient registry (https://ecrm.ctcm.nl/macro/) including patients with galactosemia from several countries. The online patient registry was established in accordance with Good Clinical Practice and is following General Data Protection Regulation. The local ethics committee of the coordinating center (Maastricht University Medical Center + (MUMC+)) approved the study (application number METC 13–4-121.6/ab) and was subsequently approved by the participating partners. Patients’ data of centers not participating in the GalNet registry were collected with Collection Forms (see Additional file 3) with similar questions as in the online registry. All patients or their authorized representatives gave written patient consent for data collection and use for scientific publication.

Patients
Data of 22 patients with GALE deficiency were collected between December 2014 and April 2022. Patients were classified as generalized or non-generalized GALE deficiency. Patients with known genotype and enzyme activities in different tissues were classified following the criteria formulated by Fridovich-Keil et al. (1993–2021) [9]. Patients who could not be categorized using these criteria, were classified based on their clinical picture and professional judgment of the treating physician. The category non-generalized included patients most likely to have peripheral or intermediate GALE deficiency (Fig. 1).

Visualization of sites of new genotypic variants
Pymol (www.pymol.org) was used to design a cartoon representation of the crystal structure of human GALE in complex with UDP-glucose and NADH. PDB-entry 1EK6 was used [40] (Fig. 2). The splice site predictions were investigated using Alamut Visual Plus v.1.3 and Genom-nis HSF Mutations Analysis Version 2.02.

Statistical analysis
Data of GALE deficient patients were exported from the database in MACRO to SPSS. Descriptive analyses were used to calculate medians and ranges for continuous variables and percentages for categorical variables. Clinical outcomes were classified as absent or present.

Abbreviations
APTT: Activated partial thromboplastin time; CDG: Congenital disorder of glycosylation; DEXA: Dual-energy X-ray absorptiometry; EBV: Epstein Barr virus; GALE: UDP-galactose-4-epimerase deficiency; GalNet: International network of galactosemias; Gal-1-P: Galactose-1-phosphate; gnomAD: Genome aggregation database; NBS: Newborn screening; PHA: Phytohemagglutinin; POI: Primary ovarian insufficiency; PT: Prothrombin time; RBC: Red blood cell; UDP-gal: Uridine diphosphate galactose; UDP-glc: Uridine diphosphate glucose; UDP-GalNAc: Uridine diphosphate-N-acetyl-galactosamine; UDP-GlcNAc: Uridine diphosphate-N-acetyl-glucosamine; WES: Whole exome sequencing; WHO: World Health Organization.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13023-022-02494-4.

Additional file 1. Detailed overview of genotype and phenotype per patient.
Additional file 2. Comparison of generalized patients with the literature.
Additional file 3. Collection forms.
Acknowledgements
We thank Prof. Judith Fridovich-Keil for her constructive criticism on a previous manuscript draft. We thank Prof. Matthias Baumgartner for providing the data of the Swiss Newborn Screening. Prof. Johannes Hübner for helping with data of 1 patient and Dr. André Schaller for sequencing the Swiss patients. We would like to thank all members of the Galactosemia Society.

Author contributions
Implementation and Coordination of registry, GaNet and conceptualization article: MER-G. Financial support grant writing for design, implementation, maintenance of the registry: MER-G. Responsible for ethical approval at the different centers, informed consent from patients, collecting medical data and entry of the data: all authors. Curation of data: BD, MER-G. Data analysis and interpretation: BD, DD, GTB, MER-G. Manuscript writing: BD, MER-G. Visualization: BD, SB, DJT, MER-G. Guarantor of article: MER-G. Manuscript editing and final approval: all authors. All authors read and approved the final manuscript.

Funding
This work was financially supported by several foundations. A grant from The Netherlands Organisation for Scientific Research to M.E.R-G. financially supported the GaNet meeting to discuss the registry. The Dutch Galactosemia Research foundation, European Galactosemia Society and Metakids grants to M.E.R-G. financed the development, implementation, maintenance and analysis of the GaNet registry. The coordinating center did the data entry of all galactosemia patients for 6 of the 7 participating Dutch centers and was financially supported by a Stofwisselkracht grant to M.E.R-G. Stofwisselkracht and Metakids grant to M.E.R-G. financially supported the analysis and interpretation of the data. A grant from the Batzebar foundation of the University Hospital Maastricht to M.G. and the Galactosämie Schweiz patient organization financially supported data entry of the patients from Switzerland. Data entry for the patients from Spain was financed by the Spanish Galactosemia foundation.

Availability of data and materials
The dataset supporting the conclusions of this article is included within the article and its additional files.

Declarations

Ethics approval and consent to participate
The study was approved by the local ethics committee of the coordinating center Maastricht University Medical Center + (MUMC+) (application number METC 13–4–121.6/ab). All patients or their authorized representatives gave written patient consent for this study.

Consent for publication
All patients or their authorized representatives gave written consent for scientific publication.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Pediatrics and Clinical Genetics, Maastricht University Medical Centre +, P. Debyelaan 25, PO Box 5800, 6229 HK Maastricht, The Netherlands.2Division of Genetics and Genomics, Harvard Medical School, Boston Children’s Hospital, 3 Blackfan Circle, Center for Life Science Building, Suite 14070, Boston, MA 02115, USA.3Division of Inherited Metabolic Diseases, University Hospital, Via Orus 2/B, 35128 Padua, Italy.4Division of Paediatric Endocrinology and Metabolism, Department of Paediatrics, University Hospital Bern, Inselspital, Freiburgstrasse 15, CH-3010 Bern, Switzerland.5Division of Paediatric Endocrinology and Metabolism, National Institute of Child Health, Great Ormond Street Hospital, University College London, London, UK.6Department of Clinical Genomics and Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.7Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.8Division for Pediatrics I, Inherited Metabolic Disorders, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.9Institute of Child Health, Aghia Sophia Children’s Hospital, Thivon & Papadimitropoulou, 11527 Athens, Greece.10Adult Inherited Metabolic Disorders Department, Salford Royal NHS Foundation Trust, Stott Lane, Salford M6 8HD, Greater Manchester, UK.11School of Pharmacy and Biomolecular Sciences, University of Brighton, Huxley Building, Lewes Road, Brighton BN2 4GJ, UK.

Received: 24 May 2022 Accepted: 15 August 2022

Published online: 02 September 2022

References
1. Walter JH, Fridovich-Keil JL. Galactosemia. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, editors. The online metabolic and molecular bases of inherited disease. New York: McGraw-Hill Education; 2019.
2. McCorvie TJ, Timson DJ. UDP-galactose 4-epimerase (GALE). In: Taniguchi N, Honke K, Fukuda M, Narimatsu H, Yamaguchi Y, Angata T, editors. Handbook of glycosyltransferases and related genes. 2nd ed. New York: Springer; 2014. p. 133.
3. Thoden JB, Wohlers TM, Fridovich-Keil JL, Holden HM. Crystallographic evidence for Tyr 157 functioning as the active site base in human UDP-galactose 4-epimerase. Biochemistry (John Wiley & Sons). 2000;39(19):5691–701.
4. Maitra US, Aninkel H. Uridine diphosphate-4-keto-glucose, an intermediate in the uridine diphosphate-galactose-4-epimerase reaction. Proc Natl Acad Sci USA. 1971;68(11):2660–3.
5. Berry GT, Nissim L, Lin Z, Mazur AT, Gibson JB, Segal S. Endogenous synthesis of galactose in normal men and patients with hereditary galactosaemia. Lancet. 1995;346(8982):1073–4.
6. Wohlers TM, Christacos NC, Harreman MT, Fridovich-Keil JL. Identification and characterization of a mutation, in the human UDP-galactose-4-epimerase gene, associated with generalized epimerase-deficiency galactosemia. Am J Hum Genet. 1999;64(2):462–70.
7. Charlwood J, Clayton P, Keir G, Mian N, Winchester B. Defective galactosylation of serum transferrin in galactosialidosis. Glycobiology. 1998;8(4):351–7.
8. Saudubray JM, Baumgartner MR, Walter J. Inborn metabolic diseases. 6th ed. Springer; 2016.
9. Fridovich-Keil JL, Bean L, He M, Scherer E. Epimerase Deficiency Galactosaemia. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Smith RJH, editors. GeneReviews(R). Seattle (WA) 1993–2021.
10. Openco KK, Schulz JM, Vargas CA, Otton CS, Epstein MP, Schnur RE, et al. Epimerase-deficiency galactosemia is not a binary condition. Am J Hum Genet. 2006;78(1):89–102.
11. Gitzelmann R. Deficiency of uridine diphosphate galactose 4-epimerase in blood cells of an apparently healthy infant preliminary communication. Helv Paediatr Acta. 1972;27(2):125–30.
12. Gitzelmann R, Steinmann B. Uridine diphosphate galactose 4-epimerase deficiency II. Clinical follow-up, biochemical studies and family investigation. Helv Paediatr Acta. 1973;28(6):497–510.
13. Walter JH, Roberts RE, Besley GT, Wraith JE, Cleary MA, Holton JB, et al. Generalised uridine diphosphate galactose-4-epimerase deficiency. Arch Dis Child. 1999;80(4):374–6.
14. Dias Costa F, Ferdinandusse S, Pinto C, Dias A, Keldermans L, Quelhas D, et al. Galactose epimerase deficiency: expanding the phenotype. JIMD Rep. 2017;37:19–25.
15. Holton JB, Gillett MG, Macaulay R, Young R. Galactosaemia: a new severe variant due to uridine diphosphate-galactose-4-epimerase deficiency. Arch Dis Child. 1981;56(1):885–7.
16. UDP-Galactose-4-Epimerase; GALE Johns Hopkins University, Baltimore, MD.OMIM® [updated 28 April 2020. Available from: https://www.omim.org/entry/606953]

17. Henderson MJ, Holton JB, MacFaul R. Further observations in a case of uridine diphosphate galactose-4-epimerase deficiency with a severe clinical presentation. J Inherit Metab Dis. 1983;6(1):17–20.

18. Schulz JM, Ross KL, Malmstrom K, Krieger M, Fridovich-Keil JL. Mediators of galactose sensitivity in UDP-galactose 4'-epimerase-impaired mammalian cells. J Biol Chem. 2005;280(14):13493–502.

19. Rubio-Gozalbo ME, Bosch AM, Burlina A, Berry GT, Treacy EP. Steering committee on behalf of all Galactosemia Network r. The galactosemia network (GalNet). J Inherit Metab Dis. 2017;40(2):169–70.

20. Garibaldi LR, Canini S, Superti-Furga A, Lamedica G, Filocamo M, Marchese N, et al. Galactosemia caused by generalized uridine diphosphate galactose-4-epimerase deficiency. J Pediatr. 1983;103(6):927–30.

21. Sardharwalla IB, Wraith JE, Bridge C, Fowler B, Roberts SA. A patient with severe type of epimerase deficiency galactosaemia. J Inherit Metab Dis. 1988;11(Suppl 2):246–9.

22. Sarkar M, Bose SS, Mondal G, Chatterjee S. Generalized epimerase deficiency galactosaemia. Indian J Pediatr. 2010;77(8):909–10.

23. Rubio-Gozalbo ME, Haskovic M, Bosch AM, Burnyte B, Coelho AI, Cassiman D, et al. The natural history of classic galactosemia: lessons from the GalNet registry. Orphanet J Rare Dis. 2019;14(1):86.

24. Alano A, Almashanu S, Chinsky JM, Costeas P, Blitzler MG, Wulfberg EA, et al. Molecular characterization of a unique patient with epimerase-deficiency galactosaemia. J Inherit Metab Dis. 1998;21(4):341–50.

25. Vitrikas K, Savard D, Bucay M. Developmental delay: when and how to screen. Am Fam Phys. 2017;96(1):36–43.

26. Abramowski A, Ward R, Hamdan AH. Neonatal hypoglycemia. StatPearls [Internet] Treasure Island (FL): StatPearls; 2021.

27. Improvement PCOQ, Hyperbilirubinemia SO. Practice parameter: management of hyperbilirubinemia in the healthy term newborn. Pediatrics. 1994;94(4):558–65.

28. Timson DJ, Lindert S. Comparison of dynamics of wildtype and V94M human UDP-galactose 4-epimerase: A computational perspective on severe epimerase-deficiency galactosaemia. Gene. 2013;526(2):318–24.

29. Waslenko J, Lucas ME, Thoden JB, Holden HM, Fridovich-Keil JL. Functional characterization of the K257R and G319E-hGALE alleles found in patients with ostensibly peripheral epimerase deficiency galactosaemia. Mol Genet Metab. 2005;84(1):32–8.

30. McCorvie TJ, Timson DJ. In silico prediction of the effects of mutations in the human UDP-galactose 4-epimerase gene towards a predictive framework for type III galactosemia. Gene. 2013;524(2):95–104.

31. Timson DJ. Functional analysis of disease-causing mutations in human UDP-galactose 4-epimerase. FEBS J. 2005;272(23):6170–7.

32. Holton JB, Walter JH, Tyfield LA. The metabolic & molecular bases of inherited disease. 8th ed. CR S, AL B, WS S, editors. New York: McGraw Hill; 2001.

33. Febres-Aldana CA, Pelaez L, Wright MS, Maher OM, Febres-Aldana AJ, Sasaki J, et al. A case of UDP-galactose 4' epimerase deficiency associated with dysmaturity and atrioventricular valve malformations: an exceptional clinical phenotype explained by altered N-glycosylation with relative preservation of the leloir pathway. Mol Syndromol. 2020;11(5–6):320–9.

34. Broussard A, Florwick A, Desbiens C, Nischan N, Robertson C, Guan Z, et al. Human UDP-galactose-4-epimerase (GALE) is required for cell-surface glycophicyte structure and function. J Biol Chem. 2020;295(5):1225–39.

35. Sturiale L, Barone R, Fiumara A, Perez M, Zaffanello M, Sorge G, et al. Hypoglycosylation with increased fucosylation and branching of serum transferrin N-glycans in untreated galactosemia. Glycobiology. 2005;15(12):1268–76.

36. Seo A, Guisiner S, Pierce S, Ben-Harosh M, Shales H, Walsh T, et al. Inherited thrombocytopenia associated with mutation of UDP-galactose-4-epimerase (GALE). Hum Mol Genet. 2019;28(1):133–42.

37. Markovitz R, Owen N, Satter LF, Krik K, Mahoney DH, Bertuch AA, et al. Expansion of the clinical phenotype of GALE deficiency. Am J Med Genet A. 2021;185(10):3118–21.

38. Ohlsson A, Guthenberg C, von Dobelin U. Galactosemia screening with low false-positive recall rate: the Swedish experience. JIMD Rep. 2012;2:113–7.

39. Los E, Ford GA. Galactose 1 phosphate uridylytransferase deficiency. Treasure Island (FL): StatPearls, 2021.

40. Thoden JB, Wohlers TM, Fridovich-Keil JL, Holden HM. Crystallographic evidence for Tyr 157 functioning as the active site base in human UDP-galactose-4-epimerase. Biochemistry. 2000;39(19):5691–701.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.